So can you share a little bit about what that means to you and why this shift is so important now?

Yeah.

So I think historically and typically, you know, we've always viewed our sites as with an operational lens.

You know, what they can deliver for us, what are their activation timelines, what are their enrollment numbers and overall study abilities.

And it's a transaction.

We give you a study, and they perform.

And while that absolutely matters and is needed, site ambassadorship really begins with recognizing our sites as experts in research delivery, and more than what I kind of am referring to as, like, an execution engine.

When we see partnership between sponsors, CROs, and sites working well, what impact does that have? Give us some kind of anecdotal or evidentiary insight into not only the operational impact, but also, again, for most importantly, the patients, things like workforce sustainability and really the future of clinical trials.